JP6055784B2 - パロキセチン誘導体 - Google Patents

パロキセチン誘導体 Download PDF

Info

Publication number
JP6055784B2
JP6055784B2 JP2013556400A JP2013556400A JP6055784B2 JP 6055784 B2 JP6055784 B2 JP 6055784B2 JP 2013556400 A JP2013556400 A JP 2013556400A JP 2013556400 A JP2013556400 A JP 2013556400A JP 6055784 B2 JP6055784 B2 JP 6055784B2
Authority
JP
Japan
Prior art keywords
compound
group
acceptable salt
added
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013556400A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2013115163A1 (ja
Inventor
圭悟 田中
圭悟 田中
大貴 西岡
大貴 西岡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JPWO2013115163A1 publication Critical patent/JPWO2013115163A1/ja
Application granted granted Critical
Publication of JP6055784B2 publication Critical patent/JP6055784B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013556400A 2012-01-31 2013-01-29 パロキセチン誘導体 Expired - Fee Related JP6055784B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592896P 2012-01-31 2012-01-31
US61/592896 2012-01-31
PCT/JP2013/051858 WO2013115163A1 (ja) 2012-01-31 2013-01-29 パロキセチン誘導体

Publications (2)

Publication Number Publication Date
JPWO2013115163A1 JPWO2013115163A1 (ja) 2015-05-11
JP6055784B2 true JP6055784B2 (ja) 2016-12-27

Family

ID=48870749

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013556400A Expired - Fee Related JP6055784B2 (ja) 2012-01-31 2013-01-29 パロキセチン誘導体

Country Status (16)

Country Link
US (1) US8933100B2 (enExample)
EP (1) EP2810942B1 (enExample)
JP (1) JP6055784B2 (enExample)
KR (1) KR101950057B1 (enExample)
CN (1) CN104039777B (enExample)
AR (1) AR089837A1 (enExample)
AU (1) AU2013216123B2 (enExample)
BR (1) BR112014016197A8 (enExample)
CA (1) CA2861479C (enExample)
ES (1) ES2576082T3 (enExample)
IL (1) IL233327A (enExample)
IN (1) IN2014CN04922A (enExample)
MX (1) MX355654B (enExample)
RU (1) RU2616610C2 (enExample)
TW (1) TW201334783A (enExample)
WO (1) WO2013115163A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43313B1 (fr) * 2015-09-02 2022-06-30 Trevena Inc Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation
CN110446495B (zh) 2017-02-17 2023-09-05 特维娜有限公司 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
CN111533682B (zh) * 2020-05-29 2022-03-01 清华大学 帕罗西汀及其类似物的制备方法
CN116406268A (zh) 2020-10-27 2023-07-07 特维娜有限公司 δ-阿片样物质调节剂的结晶和无定形形式

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
JP2002503248A (ja) 1997-06-10 2002-01-29 シントン・ベスローテン・フェンノートシャップ ４−フェニルピペリジン化合物
IT1308629B1 (it) * 1999-02-23 2002-01-09 Recordati Chem Pharm Processo per la produzione di paroxetina.
CN101273024A (zh) * 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物

Also Published As

Publication number Publication date
IL233327A (en) 2016-03-31
KR101950057B1 (ko) 2019-02-19
CA2861479C (en) 2017-10-10
IL233327A0 (en) 2014-08-31
CN104039777B (zh) 2016-03-02
AR089837A1 (es) 2014-09-17
EP2810942B1 (en) 2016-03-30
CA2861479A1 (en) 2013-08-08
EP2810942A4 (en) 2015-07-01
CN104039777A (zh) 2014-09-10
ES2576082T3 (es) 2016-07-05
TW201334783A (zh) 2013-09-01
RU2014126321A (ru) 2016-03-20
AU2013216123B2 (en) 2016-10-20
RU2616610C2 (ru) 2017-04-18
US8933100B2 (en) 2015-01-13
EP2810942A1 (en) 2014-12-10
US20130197033A1 (en) 2013-08-01
MX355654B (es) 2018-04-26
JPWO2013115163A1 (ja) 2015-05-11
KR20140117454A (ko) 2014-10-07
IN2014CN04922A (enExample) 2015-09-18
MX2014007620A (es) 2014-09-15
WO2013115163A1 (ja) 2013-08-08
BR112014016197A8 (pt) 2017-07-04
AU2013216123A1 (en) 2014-07-17
BR112014016197A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
JP7033141B2 (ja) メニン－ｍｌｌ相互作用の縮合二環式阻害剤
JP2022070895A (ja) ニューロキニン－１受容体アンタゴニストとしての化合物およびその使用
CN105473578A (zh) 用于治疗抗药性和持续性结核病的化合物
KR20190032613A (ko) (s)-7-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)-4,5,6,7-테트라-하이드로피라졸로 [1,5-a] 피리미딘-3-카르복스아미드의 제조 및 그 용도
TWI299992B (en) Naphthaline derivatives
JP2008540424A (ja) ｓＥＨインヒビターとしてのアシルヒドラゾンの使用方法
JPWO2013115163A1 (ja) パロキセチン誘導体
JP5829689B2 (ja) ピロリジン−３−イル酢酸誘導体
JP6144631B2 (ja) シタキセンタン誘導体
WO2013115167A1 (ja) アムバチニブ誘導体
CN109963834A (zh) 可用作皮质儿茶酚胺能神经传递调节剂的新型氮杂环丁烷衍生物
JP6185650B2 (ja) ５−ｈｔ４受容体アゴニストとしての５−アミノ−キノリン−８−カルボキサミド誘導体
JP2016003186A (ja) フタラン環含有アデノシンａ２ａ受容体拮抗薬
Gaali Design and Synthesis of Selective Ligands for the FK506-binding Protein 51

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161205

R150 Certificate of patent or registration of utility model

Ref document number: 6055784

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees